FDA Issues Draft Guidance for Psychedelic Research

The FDA's draft guidance outlines key considerations for researchers, including study design, safety measures, and protocols for obtaining and manufacturing psychedelic substances for clinical trials. The guidance emphasizes the need for safety evaluations, study protocols, and participant selection criteria. It also highlights the importance of addressing potential risks associated with the use of psychedelics, such as psychological effects and adverse events.